Key Points
- United Therapeutics EVP Paul Mahon sold 8,300 shares at an average price of $497.54, generating proceeds of $4.13 million and reducing his stake by 15.52% to 45,172 shares.
- The company exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, though revenue of $783.3 million missed estimates and declined 1.9% year over year.
- Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $646 consensus price target; institutional investors own 94.08% of the stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $497.54, for a total value of $4,129,582.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company's stock, valued at $22,474,876.88. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Price Performance
Shares of UTHR opened at $494.63 on Friday. United Therapeutics Corporation has a 1 year low of $408.75 and a 1 year high of $609.35. The stock has a 50 day simple moving average of $515.48 and a two-hundred day simple moving average of $540.32. The firm has a market cap of $21.21 billion, a P/E ratio of 17.70, a P/E/G ratio of 2.49 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's revenue was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $6.41 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on UTHR. Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $646.00.
Get Our Latest Report on UTHR
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Security National Bank of SO Dak bought a new stake in United Therapeutics during the 2nd quarter valued at $179,000. Talon Private Wealth LLC grew its holdings in United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company's stock worth $3,659,000 after acquiring an additional 1,630 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of United Therapeutics by 4.4% in the second quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company's stock valued at $1,371,000 after acquiring an additional 106 shares during the period. Tidal Investments LLC increased its position in shares of United Therapeutics by 1.6% in the second quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company's stock valued at $18,429,000 after acquiring an additional 547 shares during the period. Finally, Archford Capital Strategies LLC bought a new position in shares of United Therapeutics during the second quarter valued at about $552,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
